News

But it’s taking neither seriously. Despite the fact that more than 64% of people in the UK are either overweight or obese our ...
As weight-loss injections like Mounjaro and Wegovy soar in popularity across the UK, jewellers say they’re seeing an unexpected side effect: wedding and engagement rings no longer fit, and in they are ...
Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...
For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...
Medications known as GLP-1 inhibitors have made headlines in recent years due to their effectiveness in managing blood sugar ...
Ozempic could help with his as a study by Goldman Sachs found that the mass-adoption of GLP-1 series drugs could allow for ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...
These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...
Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term habits still matter most.
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.